A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia. 2020 Sep;34(9):2489-2492. doi: 10.1038/s41375-020-0778-0. Epub 2020 Feb 25.

Authors

Prithviraj Bose¹, Srdan Verstovsek¹, Jorge E Cortes¹, Susan Tse¹, Yvonne Gasior¹, Nitin Jain¹, Elias J Jabbour¹, Zeev Estrov¹, Yesid Alvarado¹, Courtney D DiNardo¹, Naveen Pemmaraju¹, Steven M Kornblau¹, Tapan M Kadia¹, Naval G Daver¹, Kiran Naqvi¹, Nicholas J Short¹, Lucia Masarova¹, John Villareal¹, Sherry A Pierce¹, Graciela Nogueras-Gonzalez², Xuelin Huang², Guillermo Garcia-Manero¹, Hagop M Kantarjian¹, Farhad Ravandi³

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. fravandi@mdanderson.org.

PMID: 32099037
DOI: 10.1038/s41375-020-0778-0

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Decitabine / administration & dosage*
Dose-Response Relationship, Drug
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Myeloproliferative Disorders / pathology*
Neoplasms, Second Primary / drug therapy*
Nitriles
Pyrazoles / administration & dosage*
Pyrimidines
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
Decitabine
ruxolitinib